Al Hamada Ali, Bruce Mieghan, Barnes Anne, Habib Ihab, D Robertson Ian
School of Veterinary Medicine, Murdoch University, Perth 6150, Australia.
College of Veterinary Medicine, University of Mosul, Mosul 41002, Iraq.
Vaccines (Basel). 2021 Aug 8;9(8):878. doi: 10.3390/vaccines9080878.
Brucellosis is a major economic and production-limiting disease for livestock owners and the community in Iraq. A cost-benefit analysis was conducted to evaluate the impact of an expanded annual mass vaccination programme of sheep and goats that involves all female and male sheep and goats over the age of 3 months with Rev. 1 vaccine. The proposed expanded vaccination programme was compared to the current annual vaccination program, which involved only vaccinating female sheep and goats between the ages of 3 and 6 months of age with Rev. 1. The cost-benefit analysis model was developed utilizing data collected in Dohuk Governorate, northern Iraq. The seroprevalence in small ruminants (using Rose Bengal test and ELISA in series) was predicted to decrease from 9.22% to 0.73% after 20 years of implementing the proposed annual mass vaccination program. The net present value of the mass vaccination program was estimated to be US$ 10,564,828 (95% Confidence Interval (CI): -16,203,454 to 37,049,245), the benefit-cost ratio was estimated to be 4.25 (95% CI: -2.71 to 11.22), and the internal rate of return was 91.38% (95% CI:11.71 to 190.62%). The proposed vaccination strategy was predicted to decrease the overall financial loss caused by brucellosis from 1.75 to 0.55 US$ per adult female animal. The results of this economic analysis highlight the benefit of implementing an annual mass vaccination program of small ruminants with Rev. 1 vaccine to reduce the prevalence of brucellosis in northern Iraq.
布鲁氏菌病对伊拉克的牲畜养殖户和社区来说是一种主要的经济和生产限制疾病。开展了一项成本效益分析，以评估一项扩大的绵羊和山羊年度大规模疫苗接种计划的影响，该计划涉及所有3个月以上的雌性和雄性绵羊和山羊，使用Rev. 1疫苗。将拟议的扩大疫苗接种计划与当前的年度疫苗接种计划进行了比较，当前计划仅对3至6个月大的雌性绵羊和山羊使用Rev. 1进行疫苗接种。利用在伊拉克北部杜胡克省收集的数据建立了成本效益分析模型。预计在实施拟议的年度大规模疫苗接种计划20年后，小型反刍动物的血清阳性率（串联使用玫瑰红试验和酶联免疫吸附测定）将从9.22%降至0.73%。大规模疫苗接种计划的净现值估计为10564828美元（95%置信区间（CI）：-16203454至37049245），效益成本比估计为4.25（95%CI：-2.71至11.22），内部收益率为91.38%（95%CI：11.71至190.62%）。预计拟议的疫苗接种策略将使布鲁氏菌病造成的总体财务损失从每只成年雌性动物1.75美元降至0.55美元。这项经济分析的结果突出了实施一项使用Rev. 1疫苗对小型反刍动物进行年度大规模疫苗接种计划以降低伊拉克北部布鲁氏菌病患病率的益处。
